Published in Antimicrob Agents Chemother on March 01, 1998
In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother (2002) 3.17
Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol (2003) 2.92
Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother (2006) 2.69
Influenza: emergence and control. J Virol (2004) 2.31
Role of tissue protection in lethal respiratory viral-bacterial coinfection. Science (2013) 2.22
Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother (2001) 2.21
Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2002) 2.21
Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother (1998) 2.19
Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother (2005) 2.17
Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother (2007) 2.03
Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother (2001) 2.00
Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother (2006) 2.00
Animal Models for Influenza Virus Pathogenesis and Transmission. Viruses (2010) 1.88
Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrob Agents Chemother (2006) 1.85
Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother (1998) 1.72
Comparison of a new neuraminidase detection assay with an enzyme immunoassay, immunofluorescence, and culture for rapid detection of influenza A and B viruses in nasal wash specimens. J Clin Microbiol (2000) 1.66
In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob Agents Chemother (2001) 1.62
Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother (2004) 1.41
Potential risks associated with the proposed widespread use of Tamiflu. Environ Health Perspect (2007) 1.39
Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother (2009) 1.37
Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. Am J Obstet Gynecol (2011) 1.36
Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother (2010) 1.31
Dependence of pathogen molecule-induced toll-like receptor activation and cell function on Neu1 sialidase. Glycoconj J (2009) 1.29
Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology (2008) 1.23
Emerging antiviral targets for influenza A virus. Trends Pharmacol Sci (2009) 1.18
In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob Agents Chemother (2002) 1.13
Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo. Antimicrob Agents Chemother (2004) 1.11
In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J Virol (2002) 1.04
Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. Antiviral Res (2008) 1.03
Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection. Antimicrob Agents Chemother (2002) 1.00
Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Agents Chemother (2008) 1.00
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother (2014) 0.96
Using the Ferret as an Animal Model for Investigating Influenza Antiviral Effectiveness. Front Microbiol (2016) 0.96
Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir. Antiviral Res (2012) 0.91
Antivirals for the treatment and prevention of epidemic and pandemic influenza. Influenza Other Respir Viruses (2007) 0.91
Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir. PLoS One (2014) 0.88
Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice. Antimicrob Agents Chemother (2014) 0.84
Echinacea purpurea aerial extract alters course of influenza infection in mice. Vaccine (2010) 0.83
Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact. J Antimicrob Chemother (2014) 0.83
Antiviral drug resistance. BMJ (1998) 0.81
A chemically programmed antibody is a long-lasting and potent inhibitor of influenza neuraminidase. Chembiochem (2012) 0.80
A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head. J Virol (2014) 0.80
Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors. Antimicrob Agents Chemother (2015) 0.79
Peramivir injection in the treatment of acute influenza: a review of the literature. Infect Drug Resist (2016) 0.79
Utilization of the embryonated egg for in vivo evaluation of the anti-influenza virus activity of neuraminidase inhibitors. Med Microbiol Immunol (2005) 0.77
The mechanisms of delayed onset type adverse reactions to oseltamivir. Infect Dis (Lond) (2016) 0.77
Permeability enhancers dramatically increase zanamivir absolute bioavailability in rats: implications for an orally bioavailable influenza treatment. PLoS One (2013) 0.77
Modeling human influenza infection in the laboratory. Infect Drug Resist (2015) 0.77
Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design. PLoS One (2015) 0.76
Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice. J Virol (2016) 0.75
Chemical analysis and transplacental transfer of oseltamivir and oseltamivir carboxylic acid in pregnant rats. PLoS One (2012) 0.75
The determination of enzyme inhibitor constants. Biochem J (1953) 27.58
Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature (1993) 8.62
Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal Biochem (1979) 7.09
Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology (1974) 6.53
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med (1997) 6.23
Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health (1987) 4.87
Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol (1995) 3.82
Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc (1997) 3.69
Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol (1976) 3.61
Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother (1980) 3.60
The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins (1992) 3.44
The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J (1992) 3.21
Assessment of signs of influenza illness in the ferret model. J Virol Methods (1989) 3.07
Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol (1993) 2.94
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother (1993) 2.92
The molecular biology of influenza virus pathogenicity. Adv Virus Res (1988) 2.90
Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol (1992) 2.38
Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA (1996) 2.30
Effects of low- and high-passage influenza virus infection in normal and nude mice. Infect Immun (1977) 2.24
Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother (1994) 2.22
Evidence for a sialosyl cation transition-state complex in the reaction of sialidase from influenza virus. Eur J Biochem (1992) 1.76
Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res (1998) 1.75
Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother (1998) 1.72
The pathogenesis of infections of the mouse caused by virulent and avirulent variants of an influenza virus. J Med Microbiol (1975) 1.65
The relation of pyrexia and nasal inflammatory response to virus levels in nasal washings of ferrets infected with influenza viruses of differing virulence. Br J Exp Pathol (1977) 1.43
Effect of selenazofurin on influenza A and B virus infections of mice. Antiviral Res (1986) 1.25
GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother (1995) 1.24
Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. J Med Chem (1994) 1.21
Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob Agents Chemother (1997) 1.17
Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid. Antiviral Res (1994) 1.17
A sialic acid-derived phosphonate analog inhibits different strains of influenza virus neuraminidase with different efficiencies. J Mol Biol (1995) 1.12
The synthesis of 2,3-didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid: a potent influenza virus sialidase inhibitor. Carbohydr Res (1994) 1.11
Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res (1994) 1.00
Mucins and mucoids in relation to influenza virus action; inhibition by purified mucoid of infection and haemagglutination with the virus strain WSE. Aust J Exp Biol Med Sci (1948) 0.96
Species differences in the stereoselective hydrolysis of esmolol by blood esterases. Drug Metab Dispos (1988) 0.96
Activity of selenazofurin against influenza A and B viruses in vitro. Antimicrob Agents Chemother (1985) 0.87
Initial characterization of human thymocyte sialidase activity: evidence that this enzymatic system is not altered during the course of T-cell maturation. Int J Biochem (1994) 0.83
Characterisation of an ionisable group involved in binding and catalysis by sialidase from influenza virus. Biochem Int (1991) 0.80
Serial analysis of gene expression. Science (1995) 60.15
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 14.30
Characterization of the yeast transcriptome. Cell (1997) 11.33
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62
Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science (1995) 9.48
A public database for gene expression in human cancers. Cancer Res (1999) 8.81
Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med (1995) 8.23
The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell (1992) 8.20
RNA-binding proteins TIA-1 and TIAR link the phosphorylation of eIF-2 alpha to the assembly of mammalian stress granules. J Cell Biol (1999) 8.07
PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell (2001) 7.95
Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science (1972) 7.74
14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell (1997) 7.20
Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med (1988) 7.12
Comparison of sequence profiles. Strategies for structural predictions using sequence information. Protein Sci (2000) 6.23
Analysis of human transcriptomes. Nat Genet (1999) 6.14
Dynamic shuttling of TIA-1 accompanies the recruitment of mRNA to mammalian stress granules. J Cell Biol (2000) 5.99
The evolution of H5N1 influenza viruses in ducks in southern China. Proc Natl Acad Sci U S A (2004) 5.87
Stem cell properties of human dental pulp stem cells. J Dent Res (2002) 5.57
Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature (1992) 5.47
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ (1991) 5.45
A role for the lissencephaly gene LIS1 in mitosis and cytoplasmic dynein function. Nat Cell Biol (2000) 5.29
Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation (2000) 5.09
Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation (2001) 5.08
Ligand binding to integrins. J Biol Chem (2000) 4.94
Identification of the gene responsible for Best macular dystrophy. Nat Genet (1998) 4.89
Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother (2005) 4.89
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res (2002) 4.85
Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature (2000) 4.68
Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J (2001) 4.40
Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci U S A (1973) 4.36
VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest (2000) 4.36
Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet (1999) 4.36
Design and performance testing of quantitative real time PCR assays for influenza A and B viral load measurement. J Clin Virol (2004) 4.28
Delay or probability discounting in a model of impulsive behavior: effect of alcohol. J Exp Anal Behav (1999) 4.23
Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet (2000) 4.17
Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother (1997) 4.14
Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem (1972) 4.12
The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med (2000) 4.08
Crystal structure of the cytochrome bc1 complex from bovine heart mitochondria. Science (1997) 4.07
In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob Agents Chemother (1973) 4.04
The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. Proc Natl Acad Sci U S A (1994) 3.90
A quantum dot single-photon turnstile device. Science (2000) 3.89
High-density SNP analysis of 642 Caucasian families with rheumatoid arthritis identifies two new linkage regions on 11p12 and 2q33. Genes Immun (2006) 3.86
DNA supercoiling promotes formation of a bent repression loop in lac DNA. J Mol Biol (1987) 3.81
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol (1997) 3.79
Low grade multiple myeloma that presented as a labial swelling -- a case report. Br Dent J (2005) 3.78
APC-mediated proteolysis of Ase1 and the morphogenesis of the mitotic spindle. Science (1997) 3.73
The genome reconstruction manager: a software environment for supporting high-throughput DNA sequencing. Genomics (1994) 3.69
Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc (1997) 3.69
Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med (1992) 3.63
A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy. Nat Genet (2001) 3.52
TRAPP, a highly conserved novel complex on the cis-Golgi that mediates vesicle docking and fusion. EMBO J (1998) 3.49
HIV-1 drug resistance in newly infected individuals. JAMA (1999) 3.49
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene (2006) 3.48
Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis (2001) 3.47
Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature (1993) 3.42
Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol (2001) 3.40
Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A. J Biol Chem (2001) 3.38
Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol (2000) 3.37
Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis. Cell (1995) 3.34
A preliminary report comparing magnetic resonance coronary angiography with conventional angiography. N Engl J Med (1993) 3.32
Multiple Morphologies of "Crew-Cut" Aggregates of Polystyrene-b-poly(acrylic acid) Block Copolymers. Science (1995) 3.16
Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol (1999) 3.15
A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med (1998) 3.15
Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis. Nature (1992) 3.13
A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol Cell Biol (1991) 3.13
The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling. Proc Natl Acad Sci U S A (2000) 3.12
Sleepiness, driving, and motor vehicle crashes. Council on Scientific Affairs, American Medical Association. JAMA (1998) 3.10
PUMA, a potent killer with or without p53. Oncogene (2008) 3.09
Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun (1996) 3.08
TraI, a LuxI homologue, is responsible for production of conjugation factor, the Ti plasmid N-acylhomoserine lactone autoinducer. Proc Natl Acad Sci U S A (1994) 3.08
Identification and classification of p53-regulated genes. Proc Natl Acad Sci U S A (1999) 3.07
Tyrosine phosphorylation of vav proto-oncogene product containing SH2 domain and transcription factor motifs. Nature (1992) 3.02
Declining HIV/AIDS mortality in New York City. J Acquir Immune Defic Syndr (1999) 3.01
Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother (1998) 3.01
Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res (2001) 2.98
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Sci U S A (2001) 2.96
Association between NS3 and NS5 proteins of dengue virus type 2 in the putative RNA replicase is linked to differential phosphorylation of NS5. J Biol Chem (1995) 2.93
Sustained photobiological hydrogen gas production upon reversible inactivation of oxygen evolution in the green alga Chlamydomonas reinhardtii. Plant Physiol (2000) 2.92
Hydrogen peroxide is involved in abscisic acid-induced stomatal closure in Vicia faba. Plant Physiol (2001) 2.91
Use of disposable micro tissue culture plates for antiviral and interferon induction studies. Appl Microbiol (1971) 2.85
Proliferation and differentiation of progenitor cells in the cortex and the subventricular zone in the adult rat after focal cerebral ischemia. Neuroscience (2001) 2.84
Pathogenicity of influenza virus. Microbiol Rev (1980) 2.80
Poor oocyte quality rather than implantation failure as a cause of age-related decline in female fertility. Lancet (1991) 2.80
Ran stimulates spindle assembly by altering microtubule dynamics and the balance of motor activities. Nat Cell Biol (2001) 2.78
NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature (2005) 2.74
CCAAT enhancer- binding protein beta is required for normal hepatocyte proliferation in mice after partial hepatectomy. J Clin Invest (1998) 2.74
Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res (2000) 2.71